Treatment

AL3818 clinical trials

1 indexed studies · 1 currently recruiting

RecruitingPHASE3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
This study is looking at a new medicine called AL3818 (anlotinib) for people with advanced alveolar soft part sarcoma (ASPS). It aims to see how safe and effective it is. Currently, it's only for ASPS patients.
For: Alveolar Soft Part Sarcoma · Leiomyosarcoma · Synovial Sarcoma
United States · China · Italy